Long-Term Treatment of Refractory Myasthenia Gravis With Subcutaneous Immunoglobulin

Therapeutic Advances in Neurological Disorders - United Kingdom
doi 10.1177/1756285617722437
Full Text
Abstract

Available in full text

Date
Authors
Publisher

SAGE Publications

Related search

Treatment for Refractory Myasthenia Gravis.

Archives of Disease in Childhood
Child HealthPediatricsPerinatology
1989English

Escalation Strategies in the Treatment of Refractory Myasthenia Gravis

Neurology International Open
2018English

Subcutaneous Immunoglobulins Are a Valuable Treatment Option in Myasthenia Gravis

Journal of Clinical Neurology (Korea
Neurology
2018English

Understanding the Burden of Refractory Myasthenia Gravis

Therapeutic Advances in Neurological Disorders
NeurologyPharmacology
2019English

Experience With Intravenous Immunoglobulin in Myasthenia Gravis: A Review.

Journal of Neurology, Neurosurgery and Psychiatry
PsychiatryMental HealthNeurologySurgery
1994English

Long-Term Remission of Refractory Stiff-Man Syndrome After Treatment With Intravenous Immunoglobulin

Mayo Clinic Proceedings
Medicine
1999English

Long-Term Follow-Up of Strabismus Surgery for Patients With Ocular Myasthenia Gravis

Journal of Neuro-Ophthalmology
MedicineOphthalmologyNeurology
2013English

Rebooting the Immune System With High-Dose Cyclophosphamide for Treatment of Refractory Myasthenia Gravis

Annals of the New York Academy of Sciences
GeneticsMolecular BiologyBiochemistryNeuroscienceHistoryPhilosophy of Science
2008English

Refractory Myasthenia Gravis: Clinical Description and Literature Review

Scholars Journal of Applied Medical Sciences
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy